News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hutchison China MediTech (Chi-Med) to Outsource Development of a TCM



12/28/2009 12:58:25 PM

ChinaBio Today -- Hutchison Chi-Med will collaborate with the University of Cambridge in the UK to investigate the mechanism of one of its best-selling TCMs, the patented Shexiang Baoxin pill that is prescribed for heart disease. The SXBX pill is thought to have an angiogenesis effect. Dysfunctional angiogenesis is associated with more than 80 diseases, from cancer and diabetic eye problems to stroke. More details...

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES